Not Yet RecruitingNot Applicable

Exploring the Effects of Korean-Style Mediterranean Diet (KORMED) and Physical Activity Measurement in Patients With MGUS/SMM: A Pilot Study

South Korea20 participantsStarted 2026-01-30

Plain-language summary

This single-arm pilot study aims to evaluate the feasibility and potential health effects of a Korean-style Mediterranean diet (KORMED) and continuous physical activity measurement in patients with monoclonal gammopathy of undetermined significance (MGUS) or smoldering multiple myeloma (SMM). The study investigates whether a 12-week KORMED dietary intervention, combined with monitoring of daily step counts using a wearable device, can improve metabolic and inflammatory biomarkers, body composition, gut microbiome diversity, and quality of life. The study seeks to answer the following primary question: Is the KORMED diet feasible and achievable for MGUS/SMM patients, as measured by changes in K-MEDAS adherence scores over 12 weeks? Secondary questions include: 1. Does adherence to KORMED lead to improvements in BMI, inflammatory markers (CRP, IL-6), metabolic indicators (HOMA-IR, FLI), M-protein levels, and gut microbiome diversity? 2. Is increased daily physical activity, measured by step counts, associated with favorable changes in metabolic and clinical parameters? 3. Can combined dietary and activity-based lifestyle modification provide preliminary evidence supporting delayed disease progression in precursor plasma cell disorders?

Who can participate

Age range19 Years – 80 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: Participants must meet all of the following: Adults aged 19 to 80 years at the time of enrollment. Diagnosed with MGUS (Monoclonal Gammopathy of Undetermined Significance) or Smoldering Multiple Myeloma (SMM) according to standard criteria. Able and willing to follow a Korean-style Mediterranean diet (KORMED) for 12 weeks. Able to use a smartphone and wearable device to track daily physical activity. Willing to attend study visits and provide blood, stool, and questionnaire data at scheduled time points. Able to understand the study procedures and provide written informed consent. Exclusion Criteria: * Participants will not be eligible if they meet any of the following: Diagnosis of active multiple myeloma requiring treatment. Current participation in another interventional clinical trial. Severe liver, kidney, or heart disease that would make the diet or study procedures unsafe. Uncontrolled infection or serious medical condition that may interfere with participation. History of major gastrointestinal surgery that prevents adherence to the diet. Pregnant or breastfeeding, or planning to become pregnant during the study period. Allergy or intolerance to key components of the KORMED diet (e.g., fish, nuts, legumes) that prevents safe participation. Any condition, in the investigator's judgment, that would make participation unsafe or limit the ability to complete the study.

What they're measuring

Change in K-MEDAS Score From Baseline to 12 Weeks

Timeframe: Baseline, 12 weeks

Trial details

NCT IDNCT07305662

SponsorSeoul National University Bundang Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2026-07-15

Contact for this trial

Soo-Mee Bang, MD, PhD

+82-31-787-7039 smbang7@snu.ac.kr